Yu-Peng Ren1,2, Ru-Jia Xie3, Scott Marshall4, Liang Li1,2, Tian-Yan Zhou1,2, Wei Lu5,6,7. 1. The State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, 100191, China. 2. Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing, 100191, China. 3. Pfizer (China) Research and Development Center, Shanghai, 201203, China. 4. Pfizer Inc, Sandwich, UK. 5. The State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, 100191, China. luwei_pk@bjmu.edu.cn. 6. Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing, 100191, China. luwei_pk@bjmu.edu.cn. 7. Center of Schizophrenia, Beijing Institute for Brain Disorders, Laboratory of Brain Disorders (Capital Medical University), Ministry of Science and Technology, Beijing, 100088, China. luwei_pk@bjmu.edu.cn.
Abstract
PURPOSE: To quantify pharmacokinetic (PK) and pharmacodynamic (PD) relationships of various classes of GABAA agonists in healthy volunteers, in order to investigate the sensitivity of the biomarker responses due to differing GABAA-subtype selectivity and to explore the correlation between biomarker responses and side effects of these drugs. METHODS: A comprehensive search was conducted for published placebo-controlled clinical studies of non- and α1-selective GABAA drugs in healthy volunteers. PK/PD models were developed for concentrations and biomarker outcomes (saccadic eye movement (SEM), visual analogue scale (VAS), digit symbol substitution task (DSST), and critical flicker fusion test (CFFT)) extracted from included studies. Predicted responses and equivalent doses for biomarkers (based on predicted response) were used to compare drug effects. And the relationship between biomarkers and safety was explored by linear regression. RESULTS: A total of 2237 data from 163 articles were included. Based on PK and placebo effect modeling, linear biomarker-concentration relationships well fit the data. The α1-selective compounds had similar equivalent doses for VAS, DSST, and CFFT (4.7-6.7 mg), which were about three to seven times lower than that for SEM (14.4-35.5 mg), while such difference was less evident for non-selective drugs. DSST had the highest correlations with incidences of somnolence and dizziness. CONCLUSIONS: The integral PK/PD models of GABAA agonists were established in healthy volunteers. SEM was identified as the most sensitive biomarker in differentiating GABAA receptor α1 subtype selective compounds. The exploratory analysis implied that different relationships existed between the drug effects on biomarkers and the adverse event profiles in healthy volunteers.
PURPOSE: To quantify pharmacokinetic (PK) and pharmacodynamic (PD) relationships of various classes of GABAA agonists in healthy volunteers, in order to investigate the sensitivity of the biomarker responses due to differing GABAA-subtype selectivity and to explore the correlation between biomarker responses and side effects of these drugs. METHODS: A comprehensive search was conducted for published placebo-controlled clinical studies of non- and α1-selective GABAA drugs in healthy volunteers. PK/PD models were developed for concentrations and biomarker outcomes (saccadic eye movement (SEM), visual analogue scale (VAS), digit symbol substitution task (DSST), and critical flicker fusion test (CFFT)) extracted from included studies. Predicted responses and equivalent doses for biomarkers (based on predicted response) were used to compare drug effects. And the relationship between biomarkers and safety was explored by linear regression. RESULTS: A total of 2237 data from 163 articles were included. Based on PK and placebo effect modeling, linear biomarker-concentration relationships well fit the data. The α1-selective compounds had similar equivalent doses for VAS, DSST, and CFFT (4.7-6.7 mg), which were about three to seven times lower than that for SEM (14.4-35.5 mg), while such difference was less evident for non-selective drugs. DSST had the highest correlations with incidences of somnolence and dizziness. CONCLUSIONS: The integral PK/PD models of GABAA agonists were established in healthy volunteers. SEM was identified as the most sensitive biomarker in differentiating GABAA receptor α1 subtype selective compounds. The exploratory analysis implied that different relationships existed between the drug effects on biomarkers and the adverse event profiles in healthy volunteers.
Authors: J Montplaisir; R Hawa; H Moller; C Morin; M Fortin; J Matte; L Reinish; C M Shapiro Journal: Hum Psychopharmacol Date: 2003-01 Impact factor: 1.672
Authors: P Hoever; S de Haas; J Winkler; R C Schoemaker; E Chiossi; J van Gerven; J Dingemanse Journal: Clin Pharmacol Ther Date: 2010-04-07 Impact factor: 6.875
Authors: Ron J Keizer; Michel van Benten; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema Journal: Comput Methods Programs Biomed Date: 2010-06-02 Impact factor: 5.428
Authors: Rebecca Dias; Wayne F A Sheppard; Rosa L Fradley; Elizabeth M Garrett; Joanna L Stanley; Spencer J Tye; Simon Goodacre; Rachael J Lincoln; Susan M Cook; Rachel Conley; David Hallett; Alexander C Humphries; Sally A Thompson; Keith A Wafford; Leslie J Street; J Luis Castro; Paul J Whiting; Thomas W Rosahl; John R Atack; Ruth M McKernan; Gerard R Dawson; David S Reynolds Journal: J Neurosci Date: 2005-11-16 Impact factor: 6.167
Authors: J R Atack; D J Hallett; S Tye; K A Wafford; C Ryan; S M Sanabria-Bohórquez; Wai-Si Eng; R E Gibson; H D Burns; G R Dawson; R W Carling; L J Street; A Pike; I De Lepeleire; K Van Laere; G Bormans; J N de Hoon; A Van Hecken; R M McKernan; M G Murphy; R J Hargreaves Journal: J Psychopharmacol Date: 2010-02-15 Impact factor: 4.153
Authors: F Crestani; R Keist; J-M Fritschy; D Benke; K Vogt; L Prut; H Blüthmann; H Möhler; U Rudolph Journal: Proc Natl Acad Sci U S A Date: 2002-06-25 Impact factor: 11.205
Authors: F T Musuamba; E Manolis; N Holford; Sya Cheung; L E Friberg; K Ogungbenro; M Posch; Jwt Yates; S Berry; N Thomas; S Corriol-Rohou; B Bornkamp; F Bretz; A C Hooker; P H Van der Graaf; J F Standing; J Hay; S Cole; V Gigante; K Karlsson; T Dumortier; N Benda; F Serone; S Das; A Brochot; F Ehmann; R Hemmings; I Skottheim Rusten Journal: CPT Pharmacometrics Syst Pharmacol Date: 2017-07-19